EP3240528B1 - Topische kombination mit fipronil, permethrin and pyriproxyfen - Google Patents

Topische kombination mit fipronil, permethrin and pyriproxyfen Download PDF

Info

Publication number
EP3240528B1
EP3240528B1 EP15816892.2A EP15816892A EP3240528B1 EP 3240528 B1 EP3240528 B1 EP 3240528B1 EP 15816892 A EP15816892 A EP 15816892A EP 3240528 B1 EP3240528 B1 EP 3240528B1
Authority
EP
European Patent Office
Prior art keywords
volume
weight
permethrin
fipronil
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15816892.2A
Other languages
English (en)
French (fr)
Other versions
EP3240528A1 (de
Inventor
Nathalie Delhom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virbac SA
Original Assignee
Virbac SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virbac SA filed Critical Virbac SA
Publication of EP3240528A1 publication Critical patent/EP3240528A1/de
Application granted granted Critical
Publication of EP3240528B1 publication Critical patent/EP3240528B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Definitions

  • the present invention relates to a liquid topical veterinary pharmaceutical composition combining fipronil, permethrin and pyriproxyfen for the treatment of infestations by external parasites.
  • Pets are often infested with one or more parasites which feed on blood, such as dog or cat fleas, ticks, or else mites (responsible for mange).
  • Fleas are wingless insects, with a body that is laterally compressed and with highly developed legs, adapted for jumping. They are ectoparasites, which suck blood from mammals or birds. The some 2000 species listed belong to the order Siphonaptera. Two species of fleas are commonly encountered in Europe; they are the cat flea ( Ctenocephalides felis ) and the dog flea ( Ctenocephalides canis ) which live in the fur of the animals.
  • Flea bites cause itching, in animals and in humans.
  • the saliva of the flea secreted at each bite) can also, depending on the individual, lead to immediate or delayed allergic reactions. These reactions result in various skin lesions and itching.
  • the fleas of the Ctenocephalides genus are, moreover, intermediate hosts of Dipylidium caninum, which is a parasitic worm of the small intestine of dogs and cats. Carnivores become infested by swallowing the parasite-infested fleas. This infestation can cause anal pruritus, engorgement of the anal sacs, and also dermatitis of the perineal region. This is why it is sometimes recommended to regularly worm animals in addition to controlling fleas.
  • Ticks Rhipicephalus sp., Ixodes sp., Dermacentor sp., Amblyomma sp., etc
  • ticks can also cause the animal stress and be harmful to its health. They can also be harmful to humans.
  • the most serious problem with ticks is that they are a vector for pathogenic agents which can affect both animals and humans.
  • borreliosis Lyme disease caused by Borrelia burgdorferi
  • babesiosis piroplasmosis caused by Babesia sp .
  • rickettsiosis Ticks can also release toxins with paralyzing and inflammatory, and sometimes lethal, properties.
  • Mosquitoes Culex sp., Aedes sp., Anopheles sp., etc
  • Sand flies ( Phlebotomus sp., etc) are haematophagous insects. The sand fly is a vector insect. If it is infected, its bite transmits leishmaniasis.
  • Formulations of ectoparasiticides such as those combining derivatives of N-phenylpyrazole and of permethrin, have been known for a long time since the overlapping and the complementarity of the spectra of actions of the active agents makes them particularly advantageous in controlling parasites in agriculture and in the veterinary field where each of the active agents is commonly used.
  • the applicant has thus given itself the objective of developing a product for the prevention and treatment of infestations by external parasites, in particular fleas, in domestic animals, which has a broad spectrum of action, which is easy to administer, while having a rapid and persistent action, and the application of which to the coat of animals prevents as much as possible the appearance of crystals visible to the naked eye.
  • Fipronil is a molecule of the family of N-phenylpyrazoles, which are compounds that have a very broad spectrum of activity, including anti-parasitic activities; they are described in patent applications EP 0 295 117 and EP 0 352 944 .
  • Permethrin or (3-phenoxyphenyl)methyl ( 1RS, 3 RS, 1 RS, 3 SR )-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane-1-carboxylate ( CAS No. 52645-53-1 ), has the following chemical structure: It is a powerful neurotoxic insecticide of the pyrethroid family.
  • Pyriproxyfen is a larvicidal insecticide, which is a pyridine derivative, having the following chemical structure: It is a juvenile hormone analogue which prevents larvae from developing into an adult insect capable of reproducing.
  • the formulation developed in the context of this invention comprises, in addition to the active agents, an aliphatic cyclic carbonate (ethylene carbonate or propylene carbonate) and a cyclic or noncyclic, aliphatic polyether (in particular, diethylene glycol monoethyl ether); it is preferably topical for spot-on administration.
  • an active agent crystallization problem it should, however, be noted that no example of a composition comprises a permethrin content greater than 45 mg/100 ml.
  • the crystallization problem addressed in this application aims to prevent solid particles of formulation from being visible on the animal's coat; this problem is solved using the abovementioned crystallization inhibitor.
  • Patent application EP 1 372 622 emphasizes the advantage of formulating compositions with a high content of pyrethroids, in particular of permethrin, but it also teaches that such compositions have a tendency to crystallize at low temperature and when the pyrethroid is present in a high concentration (for instance contents greater than 50% or than 65% volume/volume). It thus proposes remedying this problem by formulating the pyrethroid(s) in an excipient composed of terpene or of a terpene derivative or of a mixture of an alkyl glycol ether with a terpene or a terpene derivative, in order to prevent or minimize crystallization of the pyrethroid(s) at low temperature.
  • the present invention relates to a liquid topical veterinary pharmaceutical composition consisting of:
  • composition does not comprise ingredients other than those explicitly mentioned.
  • the composition comprises an amount of permethrin of between 50% and 70% by weight/volume, between 50% and 60% by weight/volume, between 50% and 58% by weight/volume and between 50% and 55% by weight/volume.
  • the composition comprises between 6% and 7% by weight/volume of fipronil, and between 50% and 70% by weight/volume, between 50% and 60% by weight/volume, between 50% and 58% by weight/volume and between 50% and 55% by weight/volume of permethrin.
  • the pyriproxyfen concentration in the composition according to the invention is between 1% and 5% by weight/volume, preferentially between 2% and 3% by weight/volume and more preferentially it is 2% by weight/volume.
  • diethylene glycol monoethyl ether is quite particularly preferred.
  • the antioxidants are advantageously chosen from ethyl or propyl gallate, ⁇ -tocopherol, ascorbic acid, ascorbyl palmitate, monothioglycerol, butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA); preferably, BHT or a mixture of BHT and BHA will be used as antioxidant.
  • the antioxidant(s) preferably represent(s) approximately from 0.005% to 2% by weight/volume, and even more preferentially from 0.01% to 0.1% by weight/volume.
  • composition according to the invention consists of:
  • composition according to the invention consists of:
  • the composition according to the invention consists of: Fipronil 6.7% Permethrin 50% Pyriproxyfen 2% BHA 0.02% BHT 0.01% Diethylene glycol monoethyl ether qs 100 ml composition expressed as percentage by weight relative to the total volume of the composition.
  • the composition according to the invention consists of: Fipronil 6.7% Permethrin 50% Pyriproxyfen 2% BHA 0.03% BHT 0.02% Diethylene glycol monoethyl ether qs 100 ml composition expressed as percentage by weight relative to the total volume of the composition.
  • compositions according to the invention which are active against blood-sucking parasites, and in particular against fleas can be in particular in the form of cutaneous liquid compositions or solutions which are very easily applied, just once, at one or more spots, topically, directly to the animal's skin, generally between the shoulder blades (spot-on application).
  • the liquid compositions are therefore packaged in containers which enable the metering of said compositions, and the volume of which is less than or equal to 10 ml, and preferably between 0.1 and 10 ml and more preferentially between 0.3 and 10 ml.
  • liquid topical veterinary pharmaceutical composition consisting of:
  • Said additional active agent(s) is (are) such that the content thereof does not exceed 10% by weight relative to the total volume of the composition and preferentially does not exceed 5% and even more preferentially 3% by weight relative to the total volume of the composition.
  • the pharmaceutical composition according to the invention is preferably packaged in single-dose pipettes.
  • the pipettes can consist of one or more films, the constituent material of which can be chosen from polypropylene (PP), polyvinyl chloride (PVC), polyvinylidene chloride, cyclic olefin copolymer (COC), polychlorotrifluoroethylene (PCTFE), or derivatives thereof, taken alone or as a mixture.
  • the film is the PolybarTM sold by the company Alcan PackagingTM, which consists of a film of cyclic olefin copolymer (COC) co-extruded between two layers of polypropylene (PP). The Polybar is then backed or laminated with a BarexTM film.
  • PET polyethylene terephthalate
  • BP ChemicalsTM polyacrylonitrile sold by the company BP ChemicalsTM under the brand name BarexTM, or derivatives thereof, taken alone or in combination.
  • the volume of the composition according to the invention contained in the pipettes may be 0.44 ml, 1.1 ml, 2.2 ml, 4.4 ml or 6.6 ml. Generally, the volume is between 0.1 and 10 ml, preferentially between 0.3 and 6.6 ml and even more preferentially between 0.44 and 6.6 ml.
  • Another subject of the present application relates to a liquid pharmaceutical composition as previously described, as an anti-parasitic veterinary medicament for topical application, preferably spot-on application, for use thereof in the prevention (protection against) and/or treatment of infestations by external parasites, such as fleas, ticks, mosquitoes, sand flies and mites, in domestic animals, in particular in dogs.
  • external parasites such as fleas, ticks, mosquitoes, sand flies and mites
  • the present invention also relates to a method for the prevention and/or the treatment of infestation by external parasites, such as fleas, ticks, mosquitoes, sand flies and mites, in domestic animals, in particular in dogs, comprising the administration, preferably the topical administration, more preferably the administration by spot-on application, of a therapeutic effective amount of the liquid pharmaceutical composition as previously described.
  • external parasites such as fleas, ticks, mosquitoes, sand flies and mites
  • the preferred administration is such that said medicament is intended to be applied by direct deposit on the skin of the animal, at the level of the shoulder blades or along a dorsal line starting from the base of the tail and going back up to the neck.
  • the amount of medicament to be administered can range from approximately 0.3 to 6.6 ml in dogs, depending on the weight of the animal under consideration, and on the dosage to be adjusted according to the frequency of the treatment.
  • the present invention also relates to the use of pyriproxyfen as an inhibitor of the crystallization of a topical veterinary composition comprising fipronil and permethrin at a concentration greater than or equal to 50% by weight/volume; preferably, this use is such that the pyriproxyfen is between 1% and 10% by weight/volume and that the fipronil is between 5% and 10% by weight/volume.
  • inhibitor of the crystallization is intended to mean a compound which, when it is added to a formulation, reduces or eliminates the appearance of crystals during the application of said formulation to the coat of an animal.
  • the present invention relates to a method for preventing the crystallization of a concentrated liquid topical veterinary pharmaceutical composition consisting of fipronil and permethrin at high concentration greater than or equal to 50% by weight/volume, which consists in adding to the composition between 1% and 10% by weight/volume of pyriproxyfen.
  • the objective of the developments carried out is the development of a formulation such that the active agents do not crystallize when they are applied to the coat of animals, despite a high concentration of active agents, in particular of permethrin.
  • compositions tested Composition R1 C1 C2 C3 C4 C5 Fipronil 6.7% 6.7% 6.7% 6.7% - - Permethrin 50% - 50% - 50% - Pyriproxyfen 2% - - 3% - 3% DGME qs 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v 100% w/v/v 100% w/v
  • DGME diethylene glycol monoethyl ether
  • the objective of this study is to demonstrate the influence of a constituent in the crystallization phenomenon at ambient temperature on the glass plate model.
  • the counting instructions are the following:
  • compositions C1, C2 and C3 were deposited reveals large crystalline zones located more on the edges of the deposits, with more than 20 crystals having sizes greater than 100 ⁇ m for compositions C2 and C3; composition C1 contains smaller crystals, the size of which can range up to 20 ⁇ m, and which are on the whole of the deposit.
  • compositions R1, C4 and C5 For compositions R1, C4 and C5, the observation with the naked eye reveals no crystallization zone.
  • compositions R1 and C2 show that pyriproxyfen substantially reduces the crystallization of fipronil when it is in the presence of permethrin at high concentration.
  • composition is stored in 10 ml transparent glass bottles at various temperatures (5°C, 25°C and 40°C), in incubators in the dark.
  • composition is stable after storage for 3 months at 25°C and 40°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (9)

  1. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung, bestehend aus:
    - zwischen 2 und 10 Gewicht/Volumen-% 5-Amino-1-[2,6-dichlor-4-(trifluormethyl)phenyl]-4-(trifluormethylsulphinyl)-1H-pyrazol-3-carbonitril (Fipronil);
    - mindestens 50 Gewicht/Volumen-% Permethrin;
    - zwischen 1 und 10 Gewicht/Volumen-% Pyriproxyfen;
    - optional einem oder mehreren Antioxidationsmitteln, ausgewählt aus Ethyl- oder Propylgallat, α-Tocopherol, Ascorbinsäure, Ascorbylpalmitat, Monothioglycerin, butyliertem Hydroxytoluol (BHT) und butyliertem Hydroxyanisol (BHA);
    - in Lösung in einem organischen Lösemittel, ausgewählt aus Propylenglycolmonomethylether, Dipropylenglycol-n-butylether, Ethylenglycolmonomethylether, Ethylenglycolmonoethylether, Diethylenglycolmonoethylether und Propylenglycol und Mischungen davon.
  2. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, dass sie aus Folgendem besteht:
    - zwischen 5 und 10 Gewicht/Volumen-% Fipronil;
    - zwischen 50 und 70 Gewicht/Volumen-% Permethrin;
    - zwischen 1 und 10 Gewicht/Volumen-% Pyriproxyfen;
    - optional zwischen 0,005 und 2 Gewicht/Volumen-% BHT und/oder BHA;
    - in Lösung in einem organischen Lösemittel, ausgewählt aus Propylenglycolmonomethylether, Dipropylenglycol-n-butylether, Ethylenglycolmonomethylether, Ethylenglycolmonoethylether, Diethylenglycolmonoethylether und Propylenglycol und Mischungen davon.
  3. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass sie aus Folgendem besteht:
    - zwischen 5 und 10 Gewicht/Volumen-% Fipronil;
    - zwischen 50 und 60 Gewicht/Volumen-% Permethrin;
    - zwischen 1 und 5 Gewicht/Volumen-% Pyriproxyfen;
    - optional zwischen 0,005 und 2 Gewicht/Volumen-% BHT und/oder BHA;
    - in Lösung in einem organischen Lösemittel, ausgewählt aus Propylenglycolmonomethylether, Dipropylenglycol-n-butylether, Ethylenglycolmonomethylether, Ethylenglycolmonoethylether, Diethylenglycolmonoethylether und Propylenglycol und Mischungen davon.
  4. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass das organische Lösemittel Diethylenglycolmonoethylether ist.
  5. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass sie aus Folgendem besteht: Fipronil 6,7 % Permethrin 50 % Pyriproxyfen 2 % BHA 0,03 % BHT 0,02 % Diethylenglycolmonoethylether qs 100 ml
    Zusammensetzung ausgedrückt als Gewichtsprozentsatz bezogen auf das Gesamtvolumen der Zusammensetzung.
  6. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, dass sie in einer Einzeldosispipette verpackt ist.
  7. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung nach einem der vorstehenden Ansprüche für ihre Verwendung bei der Prävention und/oder Behandlung von Befall von Haustieren mit äußerlichen Parasiten.
  8. Flüssige, topische, tierärztliche pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 6 zur Verwendung nach Anspruch 7, dadurch gekennzeichnet, dass sie als Spot-on-Anwendung verabreicht wird.
  9. Verfahren zur Prävention der Kristallisierung einer konzentrierten flüssigen, topischen, tierärztlichen pharmazeutischen Zusammensetzung, bestehend aus Fipronil und Permethrin, wobei das Permethrin in einer hohen Konzentration von größer als oder gleich 50 Gewicht/Volumen-% vorliegt, das in der Zugabe von zwischen 1 und 10 Gewicht/Volumen-% Pyriproxyfen zu der Zusammensetzung besteht.
EP15816892.2A 2014-12-30 2015-12-15 Topische kombination mit fipronil, permethrin and pyriproxyfen Active EP3240528B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/585,804 US9392792B1 (en) 2014-12-30 2014-12-30 Topical combination of fipronil, permethrin and pyriproxyfen
PCT/IB2015/059629 WO2016108117A1 (en) 2014-12-30 2015-12-15 Topical combination of fipronil, permethrin and pyriproxyfen

Publications (2)

Publication Number Publication Date
EP3240528A1 EP3240528A1 (de) 2017-11-08
EP3240528B1 true EP3240528B1 (de) 2019-12-18

Family

ID=55025301

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15816892.2A Active EP3240528B1 (de) 2014-12-30 2015-12-15 Topische kombination mit fipronil, permethrin and pyriproxyfen

Country Status (3)

Country Link
US (1) US9392792B1 (de)
EP (1) EP3240528B1 (de)
WO (1) WO2016108117A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458018B1 (en) 2024-12-23 2025-11-04 The Hartz Mountain Corp. Solid phase compositions and manufacturing methods for ectoparasiticidal control

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713768D0 (en) 1987-06-12 1987-07-15 May & Baker Ltd Compositions of matter
GB8816915D0 (en) 1988-07-15 1988-08-17 May & Baker Ltd New compositions of matter
US5942525A (en) * 1995-05-11 1999-08-24 Ecto Development Corporation Spot treatment of animals with pyriproxyfen and an insecticide
FR2739255B1 (fr) 1995-09-29 1998-09-04 Rhone Merieux Composition antiparasitaire pour le traitement et la protection des animaux de compagnie
PE20020945A1 (es) 2001-02-08 2002-11-19 Schering Plough Ltd Composiciones parasiticidas para el control de ectoparasitos
DE102006061538A1 (de) 2006-12-27 2008-07-03 Bayer Healthcare Ag Kombinationsprodukt zur Bekämpfung von Parasiten an Tieren
EP2187740B1 (de) 2007-09-06 2015-11-04 The Hartz Mountain Corporation Verfahren zu bekämpfung von tierparasiten mittels insektenwachstumsregulatoren
US8501799B2 (en) * 2008-12-16 2013-08-06 Virbac Pharmaceutical composition containing an N-phenylpyrazole derivative, and use thereof for preparing a topical veterinary for flea control
BR112012006514A2 (pt) 2009-09-22 2015-09-08 Sergeants Pet Care Prod Inc composição de pesticida spot-on
JO3626B1 (ar) * 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
FR3000393B1 (fr) * 2012-12-27 2015-01-16 Virbac Association topique d'un n-phenylpyrazole et de permethrine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP3240528A1 (de) 2017-11-08
US20160183530A1 (en) 2016-06-30
WO2016108117A1 (en) 2016-07-07
US9392792B1 (en) 2016-07-19

Similar Documents

Publication Publication Date Title
CN102742587B (zh) 包含茚虫威的局部外用给药制剂
CN104202985B (zh) 包含氟虫腈和氯菊酯的局部组合物和使用方法发明领域
AU2008365564B2 (en) Pharmaceutical composition containing an N-phenylpyrazole derivative, and use thereof for preparing a topical veterinary drug for flea control
JP2010155844A (ja) 動物の寄生虫を抑制するための皮膚に施用する液体組成物
AU639549B2 (en) Parasiticidal composition and methods for its making and use
TWI418344B (zh) 穩定非水性之澆潑組合物
KR100897647B1 (ko) 구충제 조성물 및 사용 방법
US20100311685A1 (en) Pharmaceutical Composition Containing An N-Phenylpyrazole Derivative And Glycofurol, Use For The Preparation Of A Topical Veterinary Medicament For Combating Fleas
EP3240528B1 (de) Topische kombination mit fipronil, permethrin and pyriproxyfen
JP4677405B2 (ja) 駆虫組成物
JP2003313104A (ja) 動物の外部寄生虫駆除用スポットオン剤
RU2283590C1 (ru) Инсектоакарицидный состав для млекопитающего
EA028544B1 (ru) Ветеринарная композиция для борьбы с паразитами для накожного применения и ее применение
AU2013368970A1 (en) Pharmaceutical composition containing a derivative of N-phenylpyrazole and permethrin, and use for the production of a topical veterinary medicament
AU2013100468B4 (en) Veterinary composition
JP2003081719A (ja) 動物外部寄生虫防除用経皮投与剤
AU2015261638B2 (en) Pharmaceutical composition containing an N-phenylpyrazole derivative, and use thereof for preparing a topical veterinary drug for flea control
TW201102000A (en) Ectoparasiticidal methods and formulations
JP2004143050A (ja) 動物の外部寄生虫駆除用液剤
US10064411B1 (en) Ectoparasiticidal formulations
AU2016204099A1 (en) Veterinary composition
AU2015200617A1 (en) Veterinary composition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20181116

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191001

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015043998

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1213803

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200319

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200418

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015043998

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1213803

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191218

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

26N No opposition filed

Effective date: 20200921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201215

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201231

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231010

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251126

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251120

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251120

Year of fee payment: 11